STRM.BIO Raises $8 Million in Series Seed 2 Financing to Advance Non-Viral Gene Delivery Platform, Led by Recordati.
Amount Raised
$8 Million
Round Type
Seed
CambridgeBiotechnologyHealth CareTherapeuticsInvestors
Description
STRM.BIO, a biotechnology company pioneering non-viral delivery technologies, announced $8 million in Series Seed 2 financing. Lead investor Recordati was joined by Boehringer Ingelheim Ventures, Delos Capital, and Blue Bay Capital. This investment, combined with an $8.4 million ARPA-H award, brings the total funding raised in this round to $16.4 million. STRM.BIO aims to enhance its MV gene delivery platform focusing on rare hematological diseases.
Quick answer
STRM.BIO raised $8 Million in a Seed round, dated January 7, 2026. Investors: Boehringer Ingelheim Ventures, Delos Capital, Blue Bay Capital and Recordati. STRM.BIO is based in Cambridge, Massachusetts, United States.
- How much did STRM.BIO raise?
- STRM.BIO raised $8 Million in a Seed round on January 7, 2026.
- Who invested in STRM.BIO?
- Boehringer Ingelheim Ventures, Delos Capital, Blue Bay Capital and Recordati are named as investors in this round.
- What does STRM.BIO do?
- STRM.BIO is a biotechnology company developing a non-viral, cell-derived delivery modality that enables safe, targeted, and scalable in vivo delivery of genetic medicines.
- Where is STRM.BIO based and how big is it?
- STRM.BIO is based in Cambridge, Massachusetts, United States. Fundz records about 14 employees.
- Who are the decision-makers at STRM.BIO?
- Fundz holds 2 contacts at STRM.BIO, including the VP of Research and Development. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as STRM.BIO that raised within 45 days of this round, from Fundz verified event records.
- Altesa raised $75M (Series B) on February 19, 2026.
- Lario Therapeutics raised $2.4M (Grant) on February 19, 2026.
- Korsana Biosciences raised $175M (Series A) on February 18, 2026.
- Faeth Therapeutics raised $200M (Post-IPO Equity) on February 18, 2026.
- Sift Biosciences raised $3.7M (Pre-Seed) on February 18, 2026.
- Brainstorm Cell Therapeutics raised $1M (Post-IPO Equity) on February 13, 2026.
Who to call at STRM.BIO, and when
A new round usually means STRM.BIO is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day STRM.BIO raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at STRM.BIO, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at STRM.BIO. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment STRM.BIO raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
STRM.BIO raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.